Responsive boron biomaterials and their biomedical applications

被引:0
作者
Weizhi Chen
Xu Zhen
Wei Wu
Xiqun Jiang
机构
[1] Nanjing University,MOE Key Laboratory of High Performance Polymer Materials and Technology, Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, and Jiangsu Key Laboratory for Nanotechnology
来源
Science China Chemistry | 2020年 / 63卷
关键词
responsive biomaterials; phenylboronic acid; drug delivery system; biomedical application;
D O I
暂无
中图分类号
学科分类号
摘要
Due to the formation of dynamic boronate ester bonds between phenylboronic acid (PBA) and 1,2- and 1,3-diols, PBA-containing biomaterials show increasing applications in biomedical areas, including responsive nanobiomaterials for targeting delivery of chemical drugs, protein drugs, gene drugs and imaging agents in vitro and in vivo for detection of various bioactive molecules such as sialic acid, saccharides, adenosine triphosphate (ATP) and dopamine. With the specific reaction between PBA and sialic acid, which is overexpressed in many kinds of cancer cells, PBA has been used as a targeting moiety for tumor-targeting drug delivery. Additionally, PBA as an electron acceptor affords nanomaterials Lewis acid-base coordination with electron donor atoms such as nitrogen and oxygen, which can be exploited for developing drug delivery systems with high drug loading. Furthermore, PBA-containing materials can stoichiometric consume reactive oxygen species (ROS) and show a nucleus targeting ability. This current review outlined PBA-containing biomaterials with various responsive abilities including sialic acid-targeting, sugars-binding, ROS-response, ATP-response, dopamine-binding, and nuclear targeting. On this basis, their biomedical applications were summarized.
引用
收藏
页码:648 / 664
页数:16
相关论文
共 861 条
[1]  
Brooks WLA(2016)undefined Chem Rev 1 1375-1397
[2]  
Sumerlin BS(2012)undefined Chem Commun 1 5956-5967
[3]  
Guo Z(1979)undefined J Chromatogr A 1 1-16
[4]  
Shin I(2014)undefined Cancer Res 1 3199-3204
[5]  
Yoon J(2013)undefined Nat Rev Drug Discov 1 931-947
[6]  
Ghebregzabher M(2018)undefined Nat Rev Cancer 1 601-618
[7]  
Rufini S(2018)undefined Nat Neurosci 1 787-793
[8]  
Sapia GM(2015)undefined Nanomedicine 1 1149-1163
[9]  
Lato M(2019)undefined Adv Mater 31 1807591-3373
[10]  
Büll C(2014)undefined Chem Sci 1 3368-7652